Drug discovery

#Drug discovery #Mass spectrometry / NMR #Protein chemistry / Proteomics #Webinar

Watch now: Accelerate your discovery efforts using targeted proteomics

Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. The webinar, entitled ‘MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases‘ is now available to watch on-demand. This webinar, hosted by DDW and… Read More

Webinar date:
Supported by Evotec
#News

#Drug discovery #Genomics #OutSee

OutSee raises £2.5m and partners with o2h discovery 

Genomic and drug discovery company OutSee has closed a £2.5 million ($3.4 million) seed funding round and partnered with contract research organisation o2h discovery to develop a lead drug target candidate.  The partnership aims to launch a collaborative drug discovery programme for OutSee’s lead target candidate, identified through the company’s genomic target discovery and precision medicine… Read More

#Business & Investment #News

Bristol Myers Squibb offices
#Bristol Myers Squibb #Clinical trial #Drug discovery

Bristol Myers Squibb extends Syngene partnership 

Bristol Myers Squibb has extended its long-term research collaboration with global CRDMO Syngene until 2035.  The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery, translational sciences, pharmaceutical development and manufacturing, clinical trials, data, and information technology services, to enable seamless progression from research to commercialisation.   “At… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug discovery #Webinar

Register now: Get an inside view of AI-native science in action

This webinar, sponsored by Benchling, provides an exclusive readout of what biotech leaders need to know heading into 2026 — and how 100 AI frontrunners are translating AI into real scientific impact. Get a rare, upfront look at what the most advanced biotech teams are actually… Read More

Webinar date:
Supported by Benchling
#News

AI
#Artificial intelligence (AI) #Drug discovery #European Medicines Agency #FDA

EMA and FDA set common principles for AI in drug development

The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have jointly identified 10 principles for good artificial intelligence (AI) practice in the medicines lifecycle.  The principles give broad guidance on AI use in evidence generation and monitoring across all phases of a medicine, from early research… Read More

#Editor's Choice #Editor's Pick #News #Regulatory

#Drug development #Drug discovery #Regulatory #Whitepaper

Whitepaper: Learn how to comply with mandatory USP revision

A new whitepaper from Mettler Toledo is available for free download entitled ‘Ensure Compliance with US Pharmacopeia’. Key highlights: Comprehensive explanation of the newly revised USP General Chapters 41 and 1251 Practical advice on how to implement these revised requirements effectively Guidance to help ensure compliance with updated USP weighing… Read More

#News

Artificial Intelligence
#AI #AI / data analytics / healthtech / informatics #Drug discovery

Insitro acquires AI biotech to develop drug discovery platform 

AI therapeutics company insitro has acquired biotechnology company CombinAbleAI to complete its AI platform for drug discovery and design.   The platform, known as TherML (Therapeutic Machine Learning), will enable insitro to accelerate the generation of clinic-ready assets and reduce late-stage development risk. The company’s enhanced platform will reportedly guide both modality selection and molecular design from target discovery through developability assessment.  "Drug discovery has traditionally… Read More

#Business & Investment #News

High-throughput screening
#Assays #Biotech #Digital workflow #Drug discovery #Protein #Protein chemistry / Proteomics #Webinar

Webinar: The next evolution of high-throughput protein analysis

In this webinar, Bio-Techne unveils the next evolution of the Leo System, expanding the capabilities of Simple Western Technology for high-throughput protein analysis. The Leo System now supports integrated dual fluorescence channels—Near-Infrared (NIR) and Infrared (IR)—alongside chemiluminescence, enabling simultaneous detection of multiple targets within 96 samples in a single… Read More

#News

#Drug discovery

Guide – Accelerate your imaging research with our updated protocols guide

This imaging protocol handbook will help you accelerate your research by helping you plan and execute your imaging experiments. The guide covers main procedural steps to achieve your best results. Plan and optimise imaging experiments with clear, step-by-step procedural guidance. Master core and advanced techniques—from cell proliferation and… Read More

#Guides

#Drug discovery #Multiomics

Webinar – Unbiased exploration of biological systems: Leveraging untargeted metabolomics and lipidomics for drug discovery

This webinar, hosted by DDW and supported by Evotec, will introduce untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar will begin with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular… Read More

#Webinars

AI roadmap
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug discovery #Webinar

Register now: The next wave of AI in biotech

This webinar, sponsored by Benchling, provides an exclusive readout of what biotech leaders need to know heading into 2026 — and how 100 AI frontrunners are translating AI into real scientific impact. Get a rare, upfront look at what the most advanced biotech teams are actually… Read More

Webinar date:
Supported by Benchling
#News

NVIDIA office Paris
#Artificial intelligence (AI) #Collaboration #Drug discovery #Eli Lilly #JP Morgan Healthcare Conference #NVIDIA #Thermo Fisher Scientific

NVIDIA expands drug discovery platform, partners with Lilly

NVIDIA has announced a major expansion of NVIDIA BioNeMo, its open development platform for AI-driven biology and drug discovery, at the JP Morgan Healthcare Conference.  The platform has expanded to include:  New NVIDIA Clara open models, the RNAPro model for RNA structure prediction and the ReaSyn v2 model  BioNeMo Recipes… Read More

#Business & Investment #News #Trending News

#Biotech #bit bio #Drug discovery #Human disease models

Bit.bio to develop human cell models for drug discovery 

Biotech company bit.bio has closed a $50 million Series C funding round to scale human cell models for drug discovery.  The company aims to use the funding to accelerate the development of, and access to, its products, scale its operations globally, expand into the multi-billion toxicology market, bolster its manufacturing operations and generate industry-leading… Read More

#Business & Investment #News

#Drug discovery #Mass spectrometry / NMR #Protein chemistry / Proteomics #Webinar

Webinar: How targeted proteomics supports different stages of drug development

Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. The webinar, entitled ‘MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases‘ is now available to watch on-demand. This webinar, hosted by DDW and… Read More

Webinar date:
Supported by Evotec
#News

Microbiome
#Clinical trials #Drug discovery #Irritable Bowel Syndrome #Microbiome

EnteroBiotix announces positive results for IBS microbiome therapy  

Biopharmaceutical company EnteroBiotix has announced positive final results from its  TrIuMPH clinical trial, which is evaluating the company’s full-spectrum microbiome therapeutic for patients with irritable bowel syndrome with constipation (IBS-C) with constipation or diarrhoea (IBS-D).  The Phase IIa clinical trial included 122 UK patients and results show that EBX-102-02 demonstrated clinically meaningful improvements in the IBS symptom severity score (IBS-SSS) versus placebo. Read More

#News